Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties
We did not find evidence of a relationship between α-synuclein SAA and disease progression however α-synuclein SAA was associated with RBDSQ. Further work is needed to understand the factors influencing α-synuclein aggregation kinetics and the role of α-synuclein SAA in disease prognosis.
Authors
- Cristina Simonet (ORCID: https://orcid.org/0000-0002-5555-0283)
- Christian Mattjie (ORCID: https://orcid.org/0000-0002-3745-8686)
- Daniel Belete (ORCID: https://orcid.org/0000-0002-0026-962X)
- Alastair John Noyce (ORCID: https://orcid.org/0000-0003-3027-5497)
- Brook Huxford (ORCID: https://orcid.org/0000-0002-5908-6983)
- Jonathan P. Bestwick (ORCID: https://orcid.org/0000-0002-3088-8616)
Institutions
- Queen Mary University of London (GB)
- Barts Health NHS Trust (GB)
- Royal London Hospital (GB)
- Homerton University Hospital NHS Foundation Trust (GB)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
Publication Details
- Journal
- Movement Disorders Clinical Practice
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1002/mdc3.70434
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00